SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): July 8, 2002.
BioTime, Inc.
(Exact name of registrant as specified in its charter)
1-12830
(Commission File Number)
California 94-3127919
(State or other jurisdiction (IRS Employer
of incorporation) Identification No.)
935 Pardee Street
Berkeley, California 94710
(Address of principal executive offices)
(510) 845-9535
(Registrant's telephone number, including area code)
Statements made in this Report that are not historical facts may
constitute forward-looking statements that are subject to risks and
uncertainties that could cause actual results to differ materially from those
discussed. Such risks and uncertainties include but are not limited to those
discussed in this report and in BioTime's Annual Report on Form 10-K filed with
the Securities and Exchange Commission. Words such as "expects," "may," "will,"
"anticipates," "intends," "plans," "believes," "seeks," "estimates," and similar
expressions identify forward-looking statements.
Item 5. Other Events.
The Health Products and Food Branch, Health Canada, has approved
Hextend(R) for sale in Canada. Hextend is BioTime's proprietary hetastarch-based
plasma volume expander with lactate, multiple electrolytes, and physiological
amounts of glucose. Hextend will be marketed in Canada by Abbott Laboratories,
Limited, Canada, an affiliate of Abbott International.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
BIOTIME, INC.
Date: July 9, 2002 By /s/ Paul Segall
----------------------------------------
Paul E. Segall
Chairman and Chief Executive Officer
2